After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...
William Blair analyst Myles Minter downgraded Biohaven (BHVN) to Market Perform from Outperform. The announcement of a CRL for troriluzole in spinocerebellar ataxia halts not only a near-term source ...
Small-town pet shop wins BBB's prestigious Torch Award Government shutdown live updates; Trump administration will partially pay for SNAP benefits Trump spent 90 minutes with ‘60 Minutes’ — here’s ...
Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China Zhejiang−Hong Kong Joint Laboratory for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback